FRONTEO Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Masahiro Morimoto; hereinafter referred to as FRONTEO) is pleased to announce that in preparation for entering the US market, it has completed the trademark registration of its AI drug discovery support service "Drug Discovery AI Factory" (hereinafter referred to as DDAIF) with the US Patent and Trademark Office (USPTO) (US registration number 7665758) and has signed a consulting contract with a US consulting firm regarding strategy building and implementation with the aim of accelerating the expansion of its life science AI business.

About Drug Discovery AI Factory (DDAIF)
DDAIF is an AI drug discovery support service in which FRONTEO's drug discovery experts, who are well versed in drug discovery, use the company's specialized AI "KIBIT" and unique analysis methods to search for target molecules and indications and provide supporting hypotheses.

Utilizing FRONTEO's unique natural language processing technology (patented in Japan and the US) that discovers unknown associations from known literature information, we provide a solution that extracts unreported target molecules with high disease relevance and presents hypotheses on the underlying disease mechanisms. Since its launch in July 2023, we have been entrusted with multiple POCs since the first year, accumulating a track record that proves the high level of FRONTEO's technical capabilities, and in 7, we started co-creation projects* with multiple pharmaceutical companies and others.

* Co-creation project: A form of collaboration between a pharmaceutical company and our research team to conduct individual research and development, such as discovering new targets, indications, or biomarkers.

[Reference for co-creation projects with pharmaceutical companies]
・FRONTEO and Eisai launch co-creation project for target discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250128
・FRONTEO and Maruishi Pharmaceutical launch a co-creation project for biomarker discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250109
・FRONTEO and UBE launch co-creation project on drug repositioning using Drug Discovery AI Factory, https://www.fronteo.com/pr/20241114

■ Overview of US trademark registration
・Trademark name: Drug Discovery AI Factory
・Trademark owner: FRONTEO Co., Ltd.
- US registration number: 7665758
- US registration date: January 2025, 1

Building on its track record in Japan, FRONTEO aims to expand its AI drug discovery and life science AI businesses into the U.S. market, and will continue to contribute to the development of global drug discovery research.

 

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO supports the judgment of experts in various fields who face social issues day and night through the provision of its proprietary specialized AI "KIBIT," and creates the starting point for innovation. Unlike general-purpose AI, our proprietary natural language processing technology (patented in Japan and the United States) enables high-speed and high-precision analysis without relying on the amount of training data or computing power. In addition, by utilizing patented technology that maps (visualizes the structure) the analyzed information, "KIBIT" can directly influence the insights of experts, and in recent years, KIBIT's technology has also been used in hypothesis generation and target discovery in drug discovery.

Through KIBIT's unique technology and approach, we aim to realize the philosophy of "providing solutions that do not overlook risks and opportunities buried in records, and realizing fairness in the information society." We are promoting social implementation in various fields of legal tech AI.
Founded in August 2003, listed on TSE Mothers (currently TSE Growth) on June 8, 2007. The company operates in Japan, the United States, South Korea, and Taiwan. Obtained a first-class medical device manufacturing and sales business license and registered a controlled medical device sales business. Capital: 6 yen (as of March 26, 898,618).

*FRONTEO, KIBIT, and Drug Discovery AI Factory are registered trademarks of FRONTEO in Japan and the United States.